InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of ...
Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...
MarketBeat on MSN
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...
All Penny Stocks (English) on MSN
Biotech surges as big money backs high-stakes kidney disease push
The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory ...
Thousands of times per year, a family’s moment of joy turns to unexpected grief. A seemingly healthy infant stops smiling or ...
An unprecedented outbreak of hantavirus has rocked a luxury cruise ship off the coast of West Africa, triggering a tsunami of ...
Greg Daugherty has worked 25+ years as an editor and writer for major publications and websites. He is also the author of two books. Katie Miller is a consumer financial services expert. She worked ...
A conserved neuropeptidergic circuit directly links internal glucose levels to sweet taste sensitivity, providing a central mechanism for coupling metabolic state to feeding behavior.
Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor ...
Our immune system is much older than we think. Long before dinosaurs existed, early life forms had developed a powerful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results